WATCH: Robert Stein, MBBS, PhD, explains the rationale for conducting the OPTIMA trial in patients with early breast cancer. #bcsm #oncology Watch more of Stein’s commentary for additional trial insights! www.onclive.com/view/dr-stei...

WATCH: Peter Fecci, MD, PhD, of @cuanschutz.bsky.social, highlights the importance of innovative glioblastoma research in honor of Glioblastoma Awareness Day. #GBMAwarenessDay #GlioblastomaAwarenessDay #GBMDay Read our interview with Dr Fecci for more insights: www.onclive.com/view/car-t-c...

BREAKING🚨: The FDA has approved gedatolisib plus fulvestrant, with or without palbociclib, for patients with HR+/ HER2– locally advanced or metastatic breast cancer without a PIK3CA mutation after prior endocrine therapy #bcsm #oncology Read more: www.onclive.com/view/fda-app...

WATCH: Wen Wee Ma, MBBS, highlights a study exploring HSV-based immunotherapy in advanced NSCLC. @clevelandclinic.bsky.social #lcsm #oncology Check out our lung cancer page for more insights! www.onclive.com/clinical/lun...

WATCH: Frederick Howard, MD, discusses the importance of the appropriate use of AI tools in breast pathology practices. See our video with Dr Howard for more insights on AI in oncology! #bcsm #oncology www.onclive.com/view/dr-howa...

Miss any of the numerous pivotal phase 3 breast cancer data readouts in recent months? OncLive has you covered with an overview of the key data reshaping the treatment paradigm, along with expert perspectives #bcsm #oncology Sign up and read more: www.onclive.com/view/researc...

WATCH 👀: Elias Jabbour, MD, of @mdanderson.bsky.social discusses the significance of the @fda.gov approval of orally disintegrating nilotinib tablets for chronic myeloid leukemia. See the whole video here➡️: onclive.com/view/dr-jabb... #oncology #leusm

BREAKING🚨: The @fda.gov has approved pembrolizumab in combination with enfortumab vedotin as neoadjuvant treatment, followed by adjuvant treatment after cystectomy, in adult patients with muscle-invasive bladder cancer #blcsm #oncology www.onclive.com/view/fda-app...

BREAKING🚨: The @fda.gov has approved isatuximab for subcutaneous injection for multiple myeloma indications #mmsm #oncology Read about the specific indications and the approval: www.onclive.com/view/fda-app...

Check out insights from Peter Voorhees, MD, of Atrium Health, on the significance of data for teclistamab monotherapy in patients with relapsed/refractory multiple myeloma from the phase 3 MajesTEC-9 trial #mmsm #oncology

Miss anything at the 2026 EHA Congress? We've got you covered Experts recap some of the top data and themes to emerge across hematologic malignancies at #EHA2026 Watch 👀 and read insights from experts on what stood out during the meeting www.onclive.com/view/hematol...

WATCH: @kalinskykevin.bsky.social, of @winshipcancer.emory.edu, highlights updated data with sacituzumab govitecan plus pembrolizumab in previously untreated TNBC. Read our coverage of these data for more insights! @ascocancer.bsky.social #ASCO26 #bcsm #oncology www.onclive.com/view/sacituz...

WATCH: Javier Cortes, MD, PhD, highlights KEYNOTE-522 data with pembrolizumab in triple-negative breast cancer. #bcsm #oncology See more insights on our breast cancer page! www.onclive.com/clinical/bre...

🎙️On this episode of #BreastCancerBriefing, Sara Nunnery, MD, MSCI, and @minhtrimd.bsky.social, discuss the emergence of the oral SERD giredestrant in hormone receptor–positive, HER2-negative breast cancer management. #bcsm #oncology Watch here 📷 ➡️ www.onclive.com/view/esr1-mu...

WATCH: Ruta D. Rao, MD, explains the prognostic implications of post-surgical ctDNA status in early triple-negative breast cancer. #bcsm #oncology Watch more insights from Dr Rao on this topic on our site! www.onclive.com/view/dr-rao-...

WATCH: Saranya Chumsri, MD, spotlights the BRIA-ABC trial of Bria-IMT in metastatic breast cancer. @mayocliniccancer.bsky.social #bcsm #oncology See our breast cancer page for more insights! www.onclive.com/clinical/bre...

WATCH: @ptarantinomd.bsky.social, of @danafarber.bsky.social, highlights the DESTINY-Breast09 trial of T-DXd plus pertuzumab in HER2-positive breast cancer. #bcsm #oncology See our HER2-positive breast cancer page for more insights! www.onclive.com/clinical/her...

🚨 BREAKING 🚨: The @fda.gov approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies. #hematology #oncology www.onclive.com/view/fda-app...

Are these French words pathologies or pastries❓ At the International Society for Cutaneous Lymphomas #6WCCL, we asked Amy Musiek, MD, & Neha Mehta-Shah, MD, MSCI of Washington University School of Medicine in St. Louis Stay on top of coverage updates from the meeting: onclive.com/conference/w...

📽️ Jacob Stephen Thomas, MD, of @keck.usc.edu unpacks the safety and efficacy data from a phase 2 study of ipatasertib plus pembrolizumab in the first-line treatment of patients with metastatic HNSCC presented at @ascocancer.bsky.social #ASCO26

Following the @ascocancer.bsky.social Annual Meeting, Noa Biran, MD, broke down some of the key multiple myeloma data presented and their potential clinical implications in this rapidly evolving field #ASCO26 #mmsm #oncology Watch now: www.onclive.com/view/unpacki...

Priya Rastogi, MD, highlights the role of minimal residual disease testing in breast oncology. #bcsm #oncology Check out our breast cancer page for more insights! www.onclive.com/clinical/bre...

WATCH: Adam Brufsky, MD, PhD, of @upmchillmancc.bsky.social, discusses the SERENA-6 trial investigating camizestrant switch upon ESR1 mutation detection in ER+, HER2-negative advanced breast cancer. #bcsm #oncology See our breast cancer page for more insights! www.onclive.com/clinical/bre...

WATCH: On this episode of Breast Cancer Briefing, Sara Nunnery, MD, MSCI, and Vandana G. Abramson, MD, discuss the transformative effects of next-generation oral SERDs in hormone receptor–positive breast cancer management. #bcsm #oncology www.onclive.com/view/oral-se...

For the first time, a CAR T-cell therapy is approved for the treatment of solid tumors. China's NMPA approved satri-cel for patients with advanced CLDN18.2+/HER2– gastric/GEJ adenocarcinoma after at least 2 prior lines of therapy #oncology Read more: www.onclive.com/view/china-s...

Following data presented at @ascocancer.bsky.social #ASCO26, Bhavana “Tina” Bhatnagar, DO, outlines the significance of the frontMIND trial in high-risk DLBCL #lymsm #oncology

Glenn J. Hanna, MD, highlights the potential role of Emi-Le in the aggressive adenoid cystic carcinoma treatment paradigm. @danafarber.bsky.social @ascocancer.bsky.social #ASCO26 #hncsm #oncology Check out our video coverage for more insights on this topic! www.onclive.com/view/dr-hann...

Tuspetinib/venetoclax/azacitidine produced high CR and MRD-negativity rates across molecular subgroups of older or unfit patients newly diagnosed AML. #EHA2026 #leusm #hematology www.onclive.com/view/tuspeti...

Fixed-duration pirtobrutinib plus venetoclax and rituximab reduced the risk of progression or death by 45% in previously treated CLL. @drmdavids.bsky.social @danafarber.bsky.social @harvardmed.bsky.social #EHA2026 #leusm #lymsm Read the full story on our site! www.onclive.com/view/fixed-d...

Phase 1 data showed that INCA033989 produced rapid and durable responses as monotherapy and in a combination regimen in CALR-mutated myelofibrosis. @gstt-nhs.bsky.social #EHA2026 #hematology #oncology www.onclive.com/view/inca033...